Moneycontrol PRO

you are here: HomeNewsBusinessCompaniesBiocon partners with Eisai to markets its anti-ulcer drug in India

SHOW NAMES

Trending Topics

Sensex Live Ganesh Consumer IPO Atlanta Electricals IPO RailTel Corporation Shares GK Energy IPO GMP

business

Biocon partners with Eisai to markets its anti-ulcer drug in India

Biocon has partnered Japanese drug maker Eisai pharma to market its anti-ulcer drug Rabeprazole in India. Biocon has confirmed this development to CNBC TV18. What is the significance of this marketing deal for Biocon? Archana Shukla has the details.

first published: Mar 28, 2017 05:03 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347